Barclays’s Oncolytics Biotech ONCY Stock Holding History

Barclays’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,200	Closed	-$1.62K	–	5296
2023 Q4	$1.62K	Buy	1,200 +400	+50%	+$625	﹤0.01%	5086
2023 Q3	$1.74K	Buy	+800	New	+$1.95K	﹤0.01%	4462

Other funds holding ONCY

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's ONCY Position: Q1 2024 in Review

Barclays sold out of Oncolytics Biotech (ONCY) in Q1 2024, closing a stake of 1,200 shares — an estimated $1.62K sold.

Barclays first reported a position in ONCY in Q3 2023 and held it in 2 quarters. The position peaked at $1.74K in Q3 2023. 36 funds tracked by Wall St. Rank hold ONCY as of Q1 2024.

Barclays reported no remaining Oncolytics Biotech position as of Q1 2024 after selling out during the quarter.
Barclays sold 1,200 Oncolytics Biotech shares in Q1 2024, an estimated $1.62K.
Barclays first reported a position in Oncolytics Biotech in Q3 2023 and held it in 2 quarters.
Barclays's Oncolytics Biotech position peaked at $1.74K in Q3 2023.
36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.